Moderna, Inc. (NASDAQ:MRNA - Get Free Report) insider Shannon Thyme Klinger sold 3,471 shares of the firm's stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the completion of the sale, the insider owned 67,468 shares of the company's stock, valued at $3,373,400. The trade was a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Moderna Trading Up 0.3%
NASDAQ:MRNA opened at $47.60 on Tuesday. The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $18.89 billion, a price-to-earnings ratio of -5.84 and a beta of 1.05. The firm has a fifty day simple moving average of $49.71 and a two-hundred day simple moving average of $43.47. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $59.55.
Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing analysts' consensus estimates of ($3.02) by ($0.38). The company had revenue of $389.00 million during the quarter, compared to analyst estimates of $236.37 million. Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The company's revenue for the quarter was up 260.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($2.52) earnings per share. Analysts expect that Moderna, Inc. will post -6.51 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of research firms have weighed in on MRNA. Royal Bank Of Canada raised their price objective on shares of Moderna from $35.00 to $38.00 and gave the company a "sector perform" rating in a research note on Monday, May 4th. Morgan Stanley set a $33.00 price objective on shares of Moderna in a research note on Friday, May 1st. Jefferies Financial Group set a $37.00 price objective on shares of Moderna and gave the company a "hold" rating in a research note on Tuesday, March 3rd. Bank of America raised their price target on shares of Moderna from $32.00 to $34.00 and gave the company an "underperform" rating in a research report on Monday. Finally, Sanford C. Bernstein reissued a "market perform" rating and set a $45.00 price target on shares of Moderna in a research report on Tuesday, February 17th. Two research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and five have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Reduce" and a consensus price target of $36.60.
Read Our Latest Stock Analysis on Moderna
Institutional Trading of Moderna
Several hedge funds have recently added to or reduced their stakes in the stock. Assetmark Inc. raised its position in Moderna by 35.1% in the first quarter. Assetmark Inc. now owns 801 shares of the company's stock worth $41,000 after acquiring an additional 208 shares during the period. New Mexico Educational Retirement Board increased its stake in shares of Moderna by 1.9% in the fourth quarter. New Mexico Educational Retirement Board now owns 15,700 shares of the company's stock worth $463,000 after purchasing an additional 300 shares in the last quarter. Cromwell Holdings LLC increased its stake in shares of Moderna by 39.7% in the fourth quarter. Cromwell Holdings LLC now owns 1,200 shares of the company's stock worth $35,000 after purchasing an additional 341 shares in the last quarter. IFP Advisors Inc increased its stake in shares of Moderna by 5.4% in the fourth quarter. IFP Advisors Inc now owns 6,785 shares of the company's stock worth $200,000 after purchasing an additional 348 shares in the last quarter. Finally, Empowered Funds LLC increased its stake in shares of Moderna by 2.6% in the fourth quarter. Empowered Funds LLC now owns 13,732 shares of the company's stock worth $405,000 after purchasing an additional 353 shares in the last quarter. Institutional investors own 75.33% of the company's stock.
Moderna Company Profile
(
Get Free Report)
Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company's platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.
Moderna's flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
